Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years

Alessandro Fiocchi, MD*; Giovanbattista Pajno, MD†; Stefania La Grutta, MD‡; Francesco Pezzuto, MD§; Cristoforo Incorvaia, MD¶; Laura Sensi, MD‖; Francesco Marcucci, MD‖; and Franco Frati, MD¶

Background: The minimum age to start specific immunotherapy with inhalant allergens in children has not been clearly established, and position papers discourage its use in children younger than 5 years.

Objective: To assess the safety of high-dose sublingual-swallow immunotherapy (SLIT) in a group of children younger than 5 years.

Methods: Sixty-five children (51 boys and 14 girls; age range, 38–80 months; mean ± SD age, 60 ± 10 years; median age, 60 months) were included in this observational study. They were treated with SLIT with a build-up phase of 11 days, culminating in a top dose of 300 IR (index of reactivity) and a maintenance phase of 300 IR 3 times a week. The allergens used were house dust mites in 42 patients, grass pollen in 11 patients, olive pollen in 5 patients, Parietaria pollen in 4 patients, and cypress pollen in 3 patients. All adverse reactions and changes in the treatment schedule were compared in 2 subgroups: children 38 to 60 months old and children 61 to 80 months old.

Results: The average cumulative dose of SLIT was 36,900 IR. Adverse reactions were observed in 11 children, none of them severe enough to require discontinuation of immunotherapy. Six reactions occurred in the 60 months or younger age group and 7 in the older than 60 months age group, with no differences between these 2 groups.

Conclusion: High-dose immunotherapy in children younger than 5 years does not cause more adverse reactions than in children aged 5 to 7 years. There is no reason to forbear studies on safety and efficacy of these preparations in young children.


INTRODUCTION

Concerns over adverse reactions and compliance have led to the development of sublingual-swallow immunotherapy (SLIT) as distinct from, and in addition to, the subcutaneous administration of allergy vaccines.1–3 SLIT is gaining clinical acceptance, although no consensus exists regarding its efficacy.4 SLIT has been proposed as particularly appropriate and safe for children,5 but few safety data have targeted pediatric populations.6–10 Safety is often deduced from studies that include children but do not report their ratio to adult patients.11–15 Few studies include children younger than 5 years.6,7,16

The 1993 European Academy of Allergology and Clinical Immunology position paper advises avoidance of immunotherapy for children younger than 5 years.17 Thus, European health care professionals have been reluctant to prescribe specific immunotherapy in very young children.18 However, the 1998 World Health Organization position paper merely lists age for initiation of immunotherapy among “research needs” and advises specialist evaluation.19 The 2001 Allergic Rhinitis and Its Impact on Asthma (ARIA) Workgroup and World Health Organization document states that immunotherapy, including SLIT, should be initiated early in the disease process, but minimum age for onset of treatment is not specified.20 The 2003 Joint Task Force position paper of the American College of Asthma, Allergy and Immunology and the American Academy of Allergy, Asthma and Immunology mentions age at onset of immunotherapy as a clinical problem of “cooperation.”21 Thus, the position that “there is no absolute cut-off . . . with respect to the youngest age at which allergen immunotherapy should be considered” remains an open-ended research question.22 In clinical practice, however, prescription of specific immunotherapy is gaining ground in pediatrics. In many regions of Italy, allergy vaccines are supplied free of charge and immunotherapy is administered in hospital for a minimal fee. Thus, the number of young children receiving immunotherapy is increasing in the absence of evidence-based restraints to prescriptions. In this context, we designed a pilot study to evaluate during a 1-year period whether the 5-year cutoff point is relevant in terms of safety for children aged 3 to 7 years already receiving SLIT for asthma and/or rhinoconjunctivitis.
PATIENTS AND METHODS

Design

The study was designed as an observational, multicenter, minimization study of SLIT prescribed for the treatment of rhinoconjunctivitis and/or asthma in children younger than 7 years. Selection criteria balanced a number of diagnostic, clinical, and prognostic factors obtained from a questionnaire. Entry criteria were as follows: age between 36 and 84 months, monosensitization to pollen or mite allergen, intermittent-severe or persistent rhinoconjunctivitis according to ARIA criteria or level I or II allergic asthma according to the Global Initiative for Asthma (GINA) criteria or both rhinoconjunctivitis and asthma, and pharmacologic medication appropriate to each GINA and ARIA staging. Parents were instructed to use the following rescue medications: for rhinitis, nasal fluticasone, 50 μg (Flixonase, GlaxoSmithKline, Uxbridge, England) as a nasal spray; for conjunctivitis, levocabastine, 0.5 mg/mL (Livostin, Jansen-Cilag, Birkerød, Denmark) as ocular drops; and for asthma symptoms, salbutamol (Ventolin, GlaxoSmithKline, Uxbridge, England) as a nasal spray; for conjunctivitis, rhinitis, nasal fluticasone, 50 μg/mL. The allergen extract was graded into concentrations of 1, 10, 100, and 300 IR (index of reactivity) per milliliter. The IR is a unit of allergenic activity specific to the Stallergènes laboratory: a 100-IR extract is defined by its capacity to induce a mean wheal diameter of 7 mm in skin prick tests in a panel of 30 patients sensitized to the allergen considered. The build-up phase was performed as suggested by the manufacturer in 11 days with a top dose of 300 IR, and the maintenance phase dose was 300 IR 3 times a week. Drops were deposited under the tongue and held for 1 minute before being swallowed.

Safety

Adverse reactions and changes in treatment schedule were recorded by means of an ad hoc questionnaire. Reaction severity was classified according to a 0- to 5-point scale (Table 1). For the purpose of analysis, clinicians were allowed to rank the different reaction types as reported in Table 2. Phase of treatment (build-up or maintenance), dose that elicited the adverse reaction, and the interval between dose and reaction were recorded.

Statistical Analysis

Hypotheses were tested by the Fisher exact test, the null hypothesis being that the median adverse event scores of the children who participated in the intervention would not change because of SLIT before or after 60 months. Data were expressed as nominal categories on a binomial scale, and the distribution of adverse effects by age was analyzed by the binomial test.

RESULTS

Sixty-five children (14 girls and 51 boys; age range, 38–80 months; mean ± SD age, 60 ± 10 months; median age, 60 months) were observed. They were divided into 2 subgroups: 38 to 60 months (6 girls and 27 boys; mean ± SD age at onset, 52 ± 6.0 months) and 61 to 80 months (8 girls and 24 boys; mean ± SD age at onset, 70 ± 10.6 months). The mean duration of treatment was 246 ± 161 days. The average cumulative dose of SLIT in the study population was 36,900 ± 1,872 IR (36,200 ± 1,227 for the group 5 years or younger and 37,600 ± 2,142 in the older group). Extracts used were house dust mites in 42 patients, grass in 11 patients, and cypress pollens in 3 patients.

In the present series, SLIT, administered with a cumulative dose more than 300 times higher than the standard dose recommended with subcutaneous immunotherapy, was tolerated without adverse events in 54 of 65 cases, whereas 11 patients experienced 13 adverse reactions. Table 3 lists reactions according to patient age in the 2 groups: 6 reactions were recorded in 5 patients in the group of patients who started treatment 60 months or younger and 7 reactions were recorded in 6 patients in the group older than 60 months. Six

<table>
<thead>
<tr>
<th>Reactions</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>No reaction</td>
<td>0</td>
</tr>
<tr>
<td>Mild reaction (not requiring medical attention)</td>
<td>1</td>
</tr>
<tr>
<td>Mild-to-moderate reaction (requires medical care but neither drug treatment nor modification of SLIT schedule)</td>
<td>2</td>
</tr>
<tr>
<td>Moderate reaction (requires either SLIT schedule modification or drug treatment)</td>
<td>3</td>
</tr>
<tr>
<td>Moderate-to-severe reaction (requires both drug treatment and temporary interruption of SLIT schedule)</td>
<td>4</td>
</tr>
<tr>
<td>Severe reaction (requires emergency department visit or hospitalization)</td>
<td>5</td>
</tr>
</tbody>
</table>

Abbreviation: SLIT, sublingual-swallow immunotherapy.
Table 3. Adverse Reactions and Severity in 11 Children

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Allergen used for SLIT</th>
<th>Treatment phase</th>
<th>Age, mo</th>
<th>Symptom</th>
<th>Severity</th>
<th>Time to adverse event, min</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Grass</td>
<td>Build-up</td>
<td>46</td>
<td>Urticaria</td>
<td>2</td>
<td>&lt;30</td>
</tr>
<tr>
<td>2</td>
<td>Grass</td>
<td>Build-up</td>
<td>57</td>
<td>Urticaria</td>
<td>1</td>
<td>&lt;30</td>
</tr>
<tr>
<td>3</td>
<td>Cypress</td>
<td>Maintenance</td>
<td>58</td>
<td>Gastrointestinal (colic)</td>
<td>2</td>
<td>30–60</td>
</tr>
<tr>
<td>4</td>
<td>Mites</td>
<td>Build-up</td>
<td>59</td>
<td>Urticaria</td>
<td>2</td>
<td>30–60</td>
</tr>
<tr>
<td>5</td>
<td>Mites</td>
<td>Maintenance</td>
<td>59</td>
<td>Urticaria</td>
<td>3</td>
<td>&gt;60</td>
</tr>
<tr>
<td>6</td>
<td>Mites</td>
<td>Maintenance</td>
<td>64</td>
<td>Gastrointestinal (colic)</td>
<td>3</td>
<td>30–60</td>
</tr>
<tr>
<td>7</td>
<td>Mites</td>
<td>Maintenance</td>
<td>69</td>
<td>Gastrointestinal (vomit)</td>
<td>4</td>
<td>30–60</td>
</tr>
<tr>
<td>8</td>
<td>Mites</td>
<td>Build-up</td>
<td>74</td>
<td>Urticaria</td>
<td>2</td>
<td>&lt;30</td>
</tr>
<tr>
<td>9</td>
<td>Mites</td>
<td>Build-up</td>
<td>74</td>
<td>Urticaria</td>
<td>2</td>
<td>30–60</td>
</tr>
<tr>
<td>10</td>
<td>Mites</td>
<td>Build-up</td>
<td>75</td>
<td>Oralabial itch</td>
<td>1</td>
<td>&lt;30</td>
</tr>
<tr>
<td>11</td>
<td>Mites</td>
<td>Maintenance</td>
<td>78</td>
<td>Gastrointestinal (colic, diarrhea)</td>
<td>3</td>
<td>&lt;30</td>
</tr>
</tbody>
</table>

Abbreviation: SLIT, sublingual-swallow immunotherapy.
controlled conditions among whom the rate of adverse reactions to SLIT was 6.25% to 49%. Treatment with SLIT with house dust mites, the build-up phase, and errors in dosage and compliance are among the risk factors for systemic reactions associated with subcutaneous immunotherapy. The waiting period following injection has been set at 30 minutes, because most untoward reactions tend to be immediate. In our series, most adverse effects occurred after SLIT with house dust mites, and 53.8% of reactions occurred during the build-up phase, underscoring the critical clinical point represented by this stage of SLIT. All but 1 reaction occurred within 60 minutes of administration, suggesting another critical clinical phase. All these findings are reminiscent of data from the literature on subcutaneous immunotherapy.

The limits of the present study are those of an observational study of adverse effects, because we could not, by design, evaluate the clinical effects of SLIT in an unselected population of children. Our aim was to examine the situation during a 1-year period in the sociomedical Italian context, where allergy vaccines are more readily available for prescription.

Our data suggest that there is no reason to forbear assessing safety and efficacy of SLIT beyond this pilot study on account of age of 5 years or younger. Because the efficacy of specific immunotherapy is said to be higher among younger children, further well-controlled clinical studies are needed to establish the safety of SLIT among toddlers. These studies should also address the clinical relevance of single allergens as risk factors.

ACKNOWLEDGMENT
The authors acknowledge the contribution of Gabriel R. Bouygue to the statistical model and to the manuscript.

REFERENCES
24. Moher D, Schulz KF, Altman D, for the CONSORT group. The CONSORT statement: revised recommendations for improving


Requests for reprints should be addressed to:
Alessandro Fiocchi, MD
Macedonio Melloni Pediatric Hospital
Via Macedonio Melloni 52
20121 Milan, Italy
E-mail: allerg@tin.it